phone Call Us : 855-380-CELL

Platelet Rich Plasma (PRP) Market Expected to Reach USD 0.35 Billion Globally in 2020

Platelet Rich Plasma Market (By Types: Pure-Platelet Rich Plasma, Leukocyte-Platelet Rich Plasma and Leukocyte-Platelet Rich Fibrin; By Origin: Autologus, Allogenic and Homologus; By Applications: Orthopedic Surgery, Cosmetic Surgery, General Surgery, Neurosurgery and Other Surgeries) – Global Industry Analysis, Size, Share, Growth, Trends & Forecast 2014 – 2020

Albany, NY — (ReleaseWire) — 03/05/2015 — According to a new market report published by U.S. based market research company, Transparency Market Research “Platelet Rich Plasma Market – Global Industry Analysis, Size, Share, Growth, Trends & Forecast 2014 – 2020” the global platelet rich plasma market was valued at USD 0.16 billion in 2013 and is estimated to reach a market value of USD 0.35 billion in 2020 growing at a CAGR of 11.9% from 2014 to 2020.

Increasing number of patients suffering from orthopedic injuries, rising number of cosmetic surgeries, growing awareness about advantages and applications of PRP products and introduction of new devices and application areas are considered as the important factors driving the growth of this market. PRP products are used for improving the rate of injury healing process in sports and orthopedic diseases and as dermal fillers in cosmetic industries. Moreover, growing geriatric population is another important factor propelling the PRP market growth during the forecast period from 2014 to 2020.

In 2013, P-PRP segment is the largest type of PRP utilized globally and held more than 60% of market share in the global PRP market. Rich content of platelets and growth factors and conventional type of PRP are the key factors that contributed in the dominance of P-PRP segment. However, L-PRF is anticipated to be the fastest growing segment during the forecast period from 2014 to 2020. Large number of stem cells and leukocytes and rapid healing of injuries are the factors expected to boost growth of this market segment.

Orthopedic surgery was the largest application segment in 2013, accounting for more than 30% of the global PRP market. The dominance of this application segment was due to large number of orthopedic and sports injuries, growing geriatric population and high efficiency of PRP in treating orthopedic injuries. Multiple applications of PRP in cosmetic surgeries and its cost-effectiveness are the prominent factors catalyzing growth of this market in cosmetic surgery.

Autologus PRP accounted for the largest share of the global PRP market in 2013. However, the autologus PRP segment is anticipated to lose market share during the forecast period due to increasing emphasis on allogenic blood derived PRP products. Thus, allogenic PRP segment is expected to witness the highest growth rate during the forecast period from 2014 to 2020 due to reduced time of wound healing and high concentration of growth factors.

Geographically, in 2013 North America dominated the global PRP market and held more than 50% of the market share. Factors such as increasing number of cosmetic and orthopedic surgeries, key players domiciled in the region and strong awareness about PRP therapy and devices are supporting the dominance of the region. However, Asia-Pacific is estimated to witness strong growth and emerge as the most promising and fastest growing market during the forecast period from 2014 to 2020. The growth is expected to be driven by factors such as rapidly growing medical tourism, wide presence of local players, high geriatric population and growing awareness about PRP therapy.

The global PRP market is dominated by selective players such as Harvest Technologies Corp., Biomet, Inc., Arthrex, Inc., Arteriocyte Medical Systems Inc. and Others. Harvest Technologies Corp. w Arthrex, Inc. and Biomet, Inc. are the key players that dominated the global PRP market. Efficient PRP products and wide distribution networks are some of the key strategies adopted by these market players. Other important market players include Dr. PRP America LLC, EmCyte Corporation, Regen Lab SA, Exactech, Inc. and Cesca Therapeutics, Inc.

The global Platelet Rich Plasma (PRP) market is segmented as follows:
Global Platelet Rich Plasma (PRP) Market, by Types
Pure-Platelet Rich Plasma (P-PRP)
Leukocyte-Platelet Rich Plasma (L-PRP)
Leukocyte-Platelet Rich Fibrin (L-PRF)
Global Platelet Rich Plasma (PRP) Market, by Origin
Global Platelet Rich Plasma (PRP) Market, by Applications
Orthopedic Surgery
Cosmetic Surgery
General Surgery
Other Surgeries (Oral and Maxillofacial, Cardiothoracic, Periodontal and Urological)
Global Platelet Rich Plasma (PRP) Market, by Geography
North America
Rest of the World (RoW)

Request a Brochure of this Report:

About Transparency Market Research
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector — such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Mr. Nachiket Ghumare
90 State Street, Suite 700
Albany, NY 12207
Tel: 518-618-1030
USA – Canada Toll Free: 866-552-3453
For more information on this press release visit:
Media Relations Contact
Mr. Nachiket
Assistant Manager
Transparency Market Research
Telephone: 518-618-1030
Email: Click to Email Mr. Nachiket

Protected: Centrepid™ PC Kit Instructional Video

This content is password protected. To view it please enter your password below:

Relation Between Topical Application of Platelet-Rich Plasma and Vancomycin and Severe Deep Sternal Wound Infections After a First Median Sternotomy

Am J Cardiol. 2014 Apr 15;113(8):1415-9. doi: 10.1016/j.amjcard.2013.12.046. Epub 2014 Jan 31.

Deep sternal wound infections (DSWIs) are serious complications of sternotomy, leading to increased mortality and costs of care. Topical applications of autologous platelet concentrate and vancomycin have both shown promise in preventing DSWIs. From January 1, 1998, to November 30, 2010, 1,866 patients without previous sternotomy underwent cardiac surgery at the Baylor University Medical Center, Dallas, by a single surgeon who systematically adopted application of a paste containing vancomycin, calcium-thrombin, and platelet-rich plasma (PRP paste) to the edges of sternal wounds before closure in December 2005. A propensity-adjusted logistic regression model employing Firth’s penalized maximum likelihood method was used to assess the association between the use of the PRP paste (intervention) and the incidence of severe DSWI. Eleven patients (0.59%) developed severe DSWIs. All were among the 1,318 patients in the control group (0.83%); no severe DSWIs developed in the 548 patients in the intervention group. Both the unadjusted and adjusted associations between the study intervention and DSWI were statistically significant (unadjusted p value=0.021; adjusted p value=0.005; adjusted odds ratio=0.05, 95% confidence interval 0.01, 0.50). In conclusion, the PRP paste appears to prevent severe DSWIs.

Read the Full Text

Cost Effectiveness of Autologous Platelet-Rich Plasma for Cardiac Surgery: An Analysis of 2,000 Patients

A. N. Patel, C. H. Selzman, G. S. Kumpati, S. McKeller, D. A. Bull

University of Utah, School of Medicine, Salt Lake City

Purpose: Sternal wound complications following cardiac surgery increase morbidity, mortality, and cost. Autologous platelet-rich plasma (PRP) derived from the patient’s own blood has been used in other settings to promote successful wound healing. The goal of this study was to analyze the addition of PRP using a rapid point of care bedside system to standard wound care in all patients undergoing sternotomy for cardiac surgical procedures.

Methods: Over a 7-year period, 2,000 patients undergoing open cardiac operations requiring sternotomy were enrolled in the study. One thousand patients received standard of care sternal closure, including preoperative antibiotics and protocol-driven glycemic management. The other 1,000 patients received standard of care sternal closure plus PRP composed of platelet-rich plasma, calcium, and thrombin applied to the sternum at the time of closure. The outcomes related to wound healing, infection, readmissions, and costs were analyzed.

Results: Two thousand patients completed the study. There were no differences between the two groups with regard to age, weight, diabetes, renal dysfunction, smoking, or steroid use. There were more ventricular assist device implantations and open aortic operations in the PRP group compared to the control group. Compared to the control group, the use of PRP reduced the incidence of deep sternal wound infection from 2.0% to 0.6%*, superficial wound drainage from 8.0% to 2.0%*, and the readmission rate from 4.0% to 0.8%* (*= p<0.05). Multivariate analysis confirmed that the use of the PRP independently predicted a reduction in the incidence of deep sternal wound infection. There were no complications associated with the use of the PRP in the treatment group. Compared to the control group, the use of PRP reduced the costs associated with the development of deep and superficial wound complications from $1,256,960 to $593,791 (p<0.05).

Conclusions: The use of PRP decreases the incidence of sternal wound complications following cardiac surgery. Consequently, the use of PRP reduces the costs associated with the management of these sternal wound complications. The routine use of platelet-rich plasma should be considered for all patients undergoing sternotomy for cardiac surgical procedures.

Treatment With Platelet-Rich Plasma Is More Effective Than Placebo for Knee Osteoarthritis

Sandeep Patel,* MS, Mandeep S. Dhillon,*y MS, FAMS, Sameer Aggarwal,* Neelam Marwaha,z MD, FAMS, and Ashish Jain, z MD

Investigation performed at the Department of Orthopaedics and Department of Transfusion Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India

Background: Specific growth factors have been proposed as therapeutic proteins for cartilage repair.

Hypothesis: Platelet-rich plasma (PRP) provides symptomatic relief in early osteoarthritis (OA) of the knee.

Study Design: Randomized controlled trial; Level of evidence, 1.

Methods: A total of 78 patients (156 knees) with bilateral OA were divided randomly into 3 groups. Group A (52 knees) received a single injection of PRP, group B (50 knees) received 2 injections of PRP 3 weeks apart, and group C (46 knees) received a single injection of normal saline. White blood cell (WBC)–filtered PRP with a platelet count 3 times that of baseline (PRP type 4B) was administered in all. All the groups were homogeneous and comparable in baseline characteristics. Clinical outcome was evaluatedusing the Western Ontario and McMaster Universities Arthritis Index (WOMAC) questionnaire before treatment and at6 weeks, 3 months, and 6 months after treatment. They were also evaluated for pain by a visual analog scale, and overall satisfactionwith the procedure and complications were noted.

Results: Statistically significant improvement in all WOMAC parameters was noted in groups A and B within 2 to 3 weeks and lasting until the final follow-up at 6 months, with slight worsening at the 6-month follow-up. The mean WOMAC scores (pain, stiffness, physical function, and total score) for group A at baseline were 10.18, 3.12, 36.56, and 49.86, respectively, and at final follow-up were 5.00, 2.10, 20.08, and 27.18, respectively, showing significant improvement. Similar improvement was noted ingroup B (mean WOMAC scores at baseline: 10.62, 3.50, 39.10, and 53.20, respectively; mean WOMAC scores at final followup: 6.18, 1.88, 22.40, and 30.48, respectively). In group C, the mean WOMAC scores deteriorated from baseline (9.04, 2.70, 33.80, and 45.54, respectively) to final follow-up (10.87, 2.76, 39.46, and 53.09, respectively). The 3 groups were compared with each other, and no improvement was noted in group C as compared with groups A and B (P\.001). There was no difference between groups A and B, and there was no influence of age, sex, weight, or body mass index on the outcome. Knees with Ahlback grade 1 fared better than those with grade 2. Mild complications such as nausea and dizziness, which were of short duration, were observed in 6 patients (22.2%) in group A and 11 patients (44%) in group B.

Conclusion: A single dose of WBC-filtered PRP in concentrations of 10 times the normal amount is as effective as 2 injections to alleviate symptoms in early knee OA. The results, however, deteriorate after 6 months. Both groups treated with PRP had better results than did the group injected with saline only.

Read the Full Text

Platelet-Rich Plasma Injections for the Treatment of Hamstring Injuries: A Randomized Controlled Trial


A hamstring injury is one of the most common types of injury affecting athletes. Despite this, the optimal management of hamstring muscle injuries is not yet defined. The effect of autologous platelet-rich plasma (PRP) therapy on the recovery of hamstring injuries is unclear.


To investigate the effect of a single PRP injection in the treatment of grade 2 hamstring muscle injuries.


Randomized controlled trial; Level of evidence, 2.


Twenty-eight patients diagnosed with an acute hamstring injury were randomly allocated to autologous PRP therapy combined with a rehabilitation program or a rehabilitation program only. The primary outcome of this study was time to return to play. In addition, changes in pain severity and pain interference scores over time were examined.


Patients in the PRP group achieved full recovery significantly earlier than controls (P = .02). The mean time to return to play was 42.5 ± 20.6 days in the control group and 26.7 ± 7.0 days in the PRP group. Significantly lower pain severity scores were observed in the PRP group throughout the study. However, no significant difference in the pain interference score was found between the 2 groups.


A single autologous PRP injection combined with a rehabilitation program was significantly more effective in treating hamstring injuries than a rehabilitation program alone.

The Role of PRP in Modern Sports Injuries

[jwplayer mediaid=”188″]

Combined Use of Adipose Derived Stem Cells & Platelet Rich Plasma: Expanding Indications

[jwplayer mediaid=”186″]